First Tracks Biotherapeutics reported positive preliminary Phase 1b results for ANB033 in celiac disease, with the treatment showing statistically significant protection against gluten-induced intestinal damage and symptoms compared with placebo. 🔹 Key Highlights - 🧬 Positive Results: ANB033 showed statistically significant protection against gluten-induced intestinal damage. - 📊 Symptom Improvement: Results included improvements in intestinal structure and symptom scores. - ✅ Safety: No safety signals have been observed to date. - 📈 Stock Reaction: TRAX was quoted at $42.01, up 31%, in the supplied update. - 🔬 Development Stage: The findings are preliminary Phase 1b results; further clinical development will be needed. 💡 Why It Matters The results offer an early clinical signal for ANB033 as a potential treatment for celiac disease. The reported improvement in both intestinal damage and symptoms could support further development, but larger studies are needed to establish the treatment’s effectiveness and safety. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified